Celgene appoints Thomas Moriarty as general counsel
pharmafile | May 9, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Celgene, Moriarty
Celgene has appointed Thomas Moriarty as its new general counsel and corporate secretary.
In this position, he will be responsible for global legal strategy at Celgene and will serve on the company’s management committee.
Moriarty joins Celgene from Medco Health Solutions where he directed all legal, regulatory, public policy and corporate governance functions as general counsel and corporate secretary since 2008.
He also served as president of global pharma strategies, senior VP of pharma strategies and solutions, and senior VP of business development since joining Medco Health Solutions in 2000.
Prior to joining Medco, Moriarty held a number of leadership positions in the biopharmaceutical industry including as a senior attorney for Merck.
Related Content

NICE recommends Celgene’s REVLIMID for multiple myeloma
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …

NICE recommends Celgene’s Revlimid combo for follicular lymphoma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …






